Navigation Links
Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
Date:2/14/2011

CAMBRIDGE, Mass., Feb. 14, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the fourth quarter and year end of 2010 on Monday, February 28, 2011 after U.S. financial markets close.

Idenix management will host a conference call at 4:30 p.m. ET on Monday, February 28, 2011 to discuss the company's financial results for the fourth quarter and year end of 2010 and provide an update on the company's development programs.

To access the call please dial 800-471-3635 U.S./Canada or 706-758-9475 International and enter passcode 44647149 or to listen to a live webcast go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com. A replay of the call will also be available from February 28, 2011, 6:30 p.m. ET until March 14, 2011, 11:59 p.m. ET.  To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 44647149. An archived webcast will also be available for two weeks after the call on the Idenix website.

About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.Idenix Pharmaceuticals Contacts:Kelly Barry (617) 995-9033  (media)Eric Hoffman (617) 224-4485 (investors)
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
2. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
5. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
6. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
7. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
8. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
9. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
10. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 ... specialty clinical-stage pharmaceutical company specializing in the development of ... public offering in the United States ... each ADS representing 40 ordinary shares of the ... In addition, Therapix has granted the underwriters a ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... 2017 To mark the end of Save Your ... leader in digital imaging solutions, will showcase Canon eye care ... New York,s Jacob Javits Center from ... sponsored by the American Optometric Association, is observed annually in ... comprehensive eye exams. In recognition of this observance, Canon ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have soared 82% ... Trends Report). As travelers visit both urban destinations, they are faced with exploration ... exposure. In response, the outdoor industry has blurred the lines between fashion and ...
(Date:3/28/2017)... ... 2017 , ... Z-Medica, LLC, a leading developer and marketer ... will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 schools ... by the American College of Surgeons, U.S. Department of Defense, Department of Homeland ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... health plans work, the Self-Funding Success website has recently developed and published an ... Health Plans ” was created based on common inquiries the site’s team of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and ... thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. The ... Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud ...
Breaking Medicine News(10 mins):